 Garden City, NY, Jan. 21, 2021 GLOBE NEWSWIRE -- ProPhase Labs, Inc. NASDAQ: PRPH, a diversified medical science and technology company, today announced the closing of its previously announced public offering of 3,000,000 shares of its common stock at a public offering price of 12.50 per share, for gross proceeds of 37,500,000, before deducting underwriting discounts and commissions and offering expenses. In addition, ProPhase Labs, Inc. has granted the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock to cover over-allotments, if any, at the public offering price, less underwriting discounts and commissions. 